Canaccord Genuity Group Issues Positive Forecast for Prestige Consumer Healthcare (NYSE:PBH) Stock Price

Prestige Consumer Healthcare (NYSE:PBH) had its price target upped by analysts at Canaccord Genuity Group from $93.00 to $100.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 14.29% from the company’s previous close.

A number of other research analysts also recently commented on the stock. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. DA Davidson lifted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday. Finally, StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $92.50.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded up $0.15 during trading on Friday, reaching $87.50. The company had a trading volume of 241,453 shares, compared to its average volume of 303,511. Prestige Consumer Healthcare has a 52 week low of $60.00 and a 52 week high of $88.36. The firm’s 50-day simple moving average is $79.19 and its 200 day simple moving average is $75.34. The firm has a market capitalization of $4.32 billion, a price-to-earnings ratio of 21.22, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.46 earnings per share for the current fiscal year.

Insider Activity

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 over the last ninety days. 1.60% of the stock is currently owned by insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of PBH. Boston Trust Walden Corp purchased a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at approximately $41,785,000. Raymond James Financial Inc. acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth approximately $42,593,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Prestige Consumer Healthcare by 19.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after purchasing an additional 255,045 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at $6,342,000. Finally, Millennium Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 565.1% in the 2nd quarter. Millennium Management LLC now owns 101,218 shares of the company’s stock valued at $6,969,000 after purchasing an additional 86,000 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.